DarioHealth Corp. (NASDAQ:DRIO) Short Interest Update

DarioHealth Corp. (NASDAQ:DRIO) was the target of a large drop in short interest in the month of December. As of December 15th, there was short interest totaling 60,781 shares, a drop of 64.9% from the November 30th total of 173,193 shares. Based on an average daily volume of 23,716 shares, the days-to-cover ratio is presently 2.6 days. Currently, 1.0% of the company’s stock are short sold. Currently, 1.0% of the company’s stock are short sold. Based on an average daily volume of 23,716 shares, the days-to-cover ratio is presently 2.6 days.

DarioHealth Stock Performance

Shares of DRIO stock opened at $10.04 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 4.02 and a current ratio of 4.55. The company has a market capitalization of $67.87 million, a price-to-earnings ratio of -0.90 and a beta of 1.08. DarioHealth has a 52-week low of $5.93 and a 52-week high of $31.00. The company has a 50-day simple moving average of $12.70 and a two-hundred day simple moving average of $12.28.

Institutional Investors Weigh In On DarioHealth

An institutional investor recently raised its position in DarioHealth stock. XTX Topco Ltd lifted its holdings in shares of DarioHealth Corp. (NASDAQ:DRIO) by 229.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,511 shares of the company’s stock after purchasing an additional 43,513 shares during the period. XTX Topco Ltd owned about 0.14% of DarioHealth worth $42,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 33.39% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Wall Street Zen upgraded shares of DarioHealth from a “sell” rating to a “hold” rating in a report on Sunday, December 21st. Stifel Nicolaus set a $16.00 target price on shares of DarioHealth in a research report on Friday, November 14th. Cowen restated a “hold” rating on shares of DarioHealth in a report on Friday, November 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of DarioHealth in a research note on Monday, December 22nd. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, DarioHealth presently has a consensus rating of “Hold” and a consensus target price of $32.00.

About DarioHealth

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.